Replies to post #201351 on Biotech Values

[DewDiligence]

ADVM replaces CEO, delays clinical trial:

http://endpts.com/post-merger-gene-therapy-player-adverum-names-amber-salzman-ceo-delays-a-clinical-trial-start/

The new CEO had been CEO of Annapurna Therapeutics, the company AAVL acquired in May 2016 in what was effectively a reverse merger (#msg-122582472).